QIAGEN touts Cyclospora detection tools amid U.S. outbreak

QIAGEN N.V. (NYSE: QGEN) highlighted its molecular testing products for detecting Cyclospora cayetanensis as U.S. health authorities report more than 1,600 confirmed cases of cyclosporiasis since May 2026, along with approximately 7,000 potential cases, according to a company press release.

The foodborne parasite, which can cause prolonged diarrhea and other gastrointestinal symptoms, is not detectable through routine stool culture and requires specialized diagnostic methods.

The company's FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as one of 16 targets covering bacterial, viral, and parasitic pathogens. The test delivers results in approximately one hour from a single patient sample.

For research use only, QIAGEN also offers a digital PCR Microbial DNA Detection Assay targeting the parasite, designed for use with its QIAcuity digital PCR system. The company's QIAseq FX DNA Library Prep Kit, approved for use with PulseNet — the U.S. public health laboratory network for foodborne disease outbreak investigations — supports shotgun sequencing workflows and is also designated for research use only.

"The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN.

QIAGEN is headquartered in Venlo, Netherlands, and employs approximately 5,500 people across more than 35 locations as of June 30, 2026.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Lake Shore Bancorp (LSBK) Tops Q2 EPS by 29c
• Shutterstock's chief accounting officer to resign in August